Pancreatic ductal adenocarcinoma is the most common form of pancreatic cancer. Each year, it strikes over 50,000 Americans and kills almost all of them. There are few treatment options currently available and these focus either on pain relief or surgery and radiation therapy to prolong life. Read more . . .
A study published November 12 in Cancer Cell reports that the experimental drug GSK547 (GlaxoSmithKline, Brentford, UK) may prove effective against a deadly form of pancreatic cancer when used together with other immune-boosting therapies.